Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.9614 +0.0299 (+3.21%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 82,058
Open 0.9769
Bid (Size) 0.9303 (10)
Ask (Size) 1.010 (12)
Prev. Close 0.9315
Today's Range 0.9231 - 0.9900
52wk Range 0.8000 - 2.423
Shares Outstanding 6,795,779
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
From PharmaCyte Biotech, Inc.
Via Business Wire

Performance

YTD
-41.4%
-41.4%
1 Month
-3.8%
-3.8%
3 Month
-12.6%
-12.6%
6 Month
-43.4%
-43.4%
1 Year
-34.6%
-34.6%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024
Via InvestorPlace
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
From PharmaCyte Biotech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
From PharmaCyte Biotech, Inc.
Via Business Wire
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024
Via InvestorPlace
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
From PharmaCyte Biotech, Inc.
Via Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
From Femasys Inc.
Via GlobeNewswire
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
From PharmaCyte Biotech, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
PharmaCyte Biotech Announces Final Results of Tender Offer
From PharmaCyte Biotech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
From PharmaCyte Biotech
Via Business Wire

Frequently Asked Questions

Is PharmaCyte Biotech, Inc. - Common Stock publicly traded?
Yes, PharmaCyte Biotech, Inc. - Common Stock is publicly traded.
What exchange does PharmaCyte Biotech, Inc. - Common Stock trade on?
PharmaCyte Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PharmaCyte Biotech, Inc. - Common Stock?
The ticker symbol for PharmaCyte Biotech, Inc. - Common Stock is PMCB on the Nasdaq Stock Market
What is the current price of PharmaCyte Biotech, Inc. - Common Stock?
The current price of PharmaCyte Biotech, Inc. - Common Stock is 0.9614
When was PharmaCyte Biotech, Inc. - Common Stock last traded?
The last trade of PharmaCyte Biotech, Inc. - Common Stock was at 09/03/25 03:59 PM ET
What is the market capitalization of PharmaCyte Biotech, Inc. - Common Stock?
The market capitalization of PharmaCyte Biotech, Inc. - Common Stock is 6.53M
How many shares of PharmaCyte Biotech, Inc. - Common Stock are outstanding?
PharmaCyte Biotech, Inc. - Common Stock has 7M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.